PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

CytoSorbents, Biocon to launch CytoSorb in Malaysia

Under the terms of the agreement, Biocon has exclusive rights to distribute CytoSorb in Malaysia.
Image credit- wilhelsmen.com
CytoSorbents Corporation, a critical care immunotherapy leader using blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, recently announced the expansion of its strategic partnership with Biocon Ltd.,  Asia’s premier biopharmaceuticals company, for the distribution of CytoSorb in Malaysia.
CytoSorb, approved in the European Union (E.U.) and distributed in 45 countries worldwide, is CytoSorbents’ unique whole blood cytokine adsorber designed to reduce cytokine storm and other excessive mediators that drive a deadly inflammatory response in common life-threatening conditions seen in the intensive care unit (ICU) and during complex cardiac surgery.
Under the terms of the agreement, Biocon has exclusive rights to distribute CytoSorb in Malaysia, where CytoSorb is already registered. Similar to its approach in India, Biocon will assign a dedicated team in Malaysia to lead the market introduction and commercial development of CytoSorb.
CytoSorbents and Biocon entered into a strategic partnership in September 2013, under which Biocon was appointed as the exclusive commercialization partner for CytoSorb in India and select emerging markets.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026